1. Generics Bulletin
  2. >>Business
  3. >>Earnings

Hikma Proves Resilient In 2020 Despite Some Bumpy Launches

Rivals To Advair And Vascepa Suffer From Delays And API Scarcity

 
• By Dave Wallace

Despite turbulence in 2020 from the coronavirus pandemic as well as from difficulties relating to two of its key US generic launches, Hikma has reported solid full-year growth in both sales and profits across its business.

Plane Aeroplane Turbulence Clouds Flight
Hikma has come through turbulence in 2020 to report solid growth • Source: Shutterstock

Despite bumpy launches for two of its key generics in the US – rivals to Amarin’s Vascepa (icosapent ethyl) and GlaxoSmithKline’s Advair (fluticasone/salmeterol) – and the pressures of the COVID-19 pandemic, Hikma has nevertheless managed to deliver solid growth in 2020, with a double-digit ramp-up in operating profit outpacing a 6% turnover increase on the back of solid performances across its three key business segments.

Hikma’s overall turnover for 2020 grew by 6%, both as reported and in constant-currency terms, to $2.341bn, while the firm’s operating profit grew by 17% as reported and by 23%...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Alvotech And Advanz Add Three More In €160m EU Partnership Expansion

 
• By Dean Rudge

Fresh from filing a proposed biosimilar to Xolair (omalizumab) in the UK, Alvotech and Advanz have shaken hands on a further deal to expand their partnership.

Krka Looks To Kick On In India And China

 
• By Dean Rudge

Krka has provided updates for its pair of joint ventures in two key Asian markets, India and China, as the Slovenian firm reported its first-quarter financial results.

Zydus To Continue Mirabegron Sales

 
• By Vibha Ravi

Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list.

Sawai Reports ‘Solid Overall’ Full Year Results Despite Some Misses

 
• By Adam Zamecnik

Continuing in its medium-term business plan and company reform, Sawai forecasts its revenue to exceed ¥200bn in the coming fiscal year.

More from Business

Krka Looks To Kick On In India And China

 
• By Dean Rudge

Krka has provided updates for its pair of joint ventures in two key Asian markets, India and China, as the Slovenian firm reported its first-quarter financial results.

Teva Brings In European Trastuzumab With Prestige BioPharma Agreement

 
• By Dean Rudge

Teva will now market biosimilar Herceptin in both the US and Europe, after penning an agreement with Singaporean firm Prestige BioPharma for its Tuznue rival to the monoclonal antibody to treat HER2-positive breast cancer and HER2-positive metastatic stomach cancer.

SteinCares Deal Leads Lupin’s Ranibizumab Into Latin America

 
• By Dave Wallace

Lupin is planning to make inroads into the Latin American biosimilars market through a deal with local player SteinCares for a ranibizumab rival to Lucentis.